Merck KGaA, GSK pen $4.2B biobucks pact for next-gen Bavencio

Merck KGaA, GSK pen $4.2B biobucks pact for next-gen Bavencio

…have on the lives of cancer patients.”Dr. Belén Garijo, CEO Healthcare of Merck KGaA, added, “Our bifunctional fusion protein M7824 has the potential to bring new answers to patients living with…

7
Like
Save

Comments

Write a comment

*